Home LiteratureArticle Details
PMID: 10791994 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Proinflammatory consequences of transgenic fas ligand expression in the heart.

The Journal of clinical investigation ·Vol. 105 ·No. 9 ·2000-05-00 ·Pages 1199-208

Nelson DP, Setser E, Hall DG, Schwartz SM, Hewitt T, Klevitsky R, Osinska H, Bellgrau D, Duke RC, Robbins J

Abstract

Expression of Fas ligand (FasL) renders certain tissues immune privileged, but its expression in other tissues can result in severe neutrophil infiltration and tissue destruction. The consequences of enforced FasL expression in striated muscle is particularly controversial. To create a stable reproducible pattern of cardiomyocyte-specific FasL expression, transgenic (Tg) mice were generated that express murine FasL specifically in the heart, where it is not normally expressed. Tg animals are healthy and indistinguishable from nontransgenic littermates. FasL expression in the heart does result in mild leukocyte infiltration, but despite coexpression of Fas and FasL in Tg hearts, neither myocardial tissue apoptosis nor necrosis accompanies the leukocyte infiltration. Instead of tissue destruction, FasL Tg hearts develop mild interstitial fibrosis, functional changes, and cardiac hypertrophy, with corresponding molecular changes in gene expression. Induced expression of the cytokines TNF-alpha, IL-1beta, IL-6, and TGF-beta accompanies these proinflammatory changes. The histologic, functional, and molecular proinflammatory consequences of cardiac FasL expression are transgene-dose dependent. Thus, coexpression of Fas and FasL in the heart results in leukocyte infiltration and hypertrophy, but without the severe tissue destruction observed in other examples of FasL-directed proinflammation. The data suggest that the FasL expression level and other tissue-specific microenvironmental factors can modulate the proinflammatory consequences of FasL.

MeSH Terms
Age Factors Animals Apoptosis Cardiomegaly/pathology Cell Size Cytokines/biosynthesis Fas Ligand Protein Gene Dosage Membrane Glycoproteins/analysis,genetics Mice Mice, Transgenic Myocarditis/pathology Transforming Growth Factor beta/analysis fas Receptor/analysis
Chemicals
Cytokines Fas Ligand Protein Fasl protein, mouse Membrane Glycoproteins Transforming Growth Factor beta fas Receptor
Authors & Affiliations
10 authors, click to expand affiliations / ORCID
Nelson D P
Division of Molecular Cardiovascular Biology, and. Division of Cardiology, Department of Pediatrics, The Children's Hospital Research Foundation, Cincinnati, Ohio, USA.
Setser E
Hall D G
Schwartz S M
Hewitt T
Klevitsky R
Osinska H
Bellgrau D
Duke R C
Robbins J
References (43)
43 references, click to expand
  1. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis.
    Science. 1997 Feb 14;275(5302):960-3 PMID: 9020075
  2. Selective inhibition of protein kinase C isozymes by Fas ligation.
    J Biol Chem. 1999 May 28;274(22):15320-8 PMID: 10336417
  3. The role of Fas in autoimmune diabetes.
    Cell. 1997 Apr 4;89(1):17-24 PMID: 9094710
  4. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts.
    Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3943-7 PMID: 9108084
  5. Transgenic remodeling of the regulatory myosin light chains in the mammalian heart.
    Circ Res. 1997 May;80(5):655-64 PMID: 9130446
  6. Fas-ligand: privilege and peril.
    Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):5986-90 PMID: 9177153
  7. The Fas counterattack: a molecular mechanism of tumor immune privilege.
    Mol Med. 1997 May;3(5):294-300 PMID: 9205945
  8. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction.
    Nat Med. 1997 Jul;3(7):738-43 PMID: 9212099
  9. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice.
    J Exp Med. 1997 Aug 18;186(4):613-8 PMID: 9254659
  10. Fas- or ceramide-induced apoptosis is mediated by a Rac1-regulated activation of Jun N-terminal kinase/p38 kinases and GADD153.
    J Biol Chem. 1997 Aug 29;272(35):22173-81 PMID: 9268362
  11. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha.
    Circ Res. 1997 Oct;81(4):627-35 PMID: 9314845
  12. Contribution of Fas ligand to T cell-mediated hepatic injury in mice.
    Gastroenterology. 1997 Oct;113(4):1315-22 PMID: 9322527
  13. Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.
    J Clin Invest. 1997 Oct 15;100(8):1951-7 PMID: 9329958
  14. Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice.
    J Biol Chem. 1991 Dec 25;266(36):24613-20 PMID: 1722208
  15. Basic mechanisms in congestive heart failure. Recognizing the role of proinflammatory cytokines.
    Chest. 1994 Mar;105(3):897-904 PMID: 8131560
  16. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.
    Cell. 1994 Mar 25;76(6):969-76 PMID: 7511063
  17. The Fas death factor.
    Science. 1995 Mar 10;267(5203):1449-56 PMID: 7533326
  18. The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster.
    Immunity. 1994 May;1(2):131-6 PMID: 7889405
  19. Interleukin-1 beta induces cardiac myocyte growth but inhibits cardiac fibroblast proliferation in culture.
    J Clin Invest. 1995 Jun;95(6):2555-64 PMID: 7769098
  20. A role for CD95 ligand in preventing graft rejection.
    Nature. 1995 Oct 19;377(6550):630-2 PMID: 7566174
  21. Fas ligand-induced apoptosis as a mechanism of immune privilege.
    Science. 1995 Nov 17;270(5239):1189-92 PMID: 7502042
  22. JNK, but not MAPK, activation is associated with Fas-mediated apoptosis in human T cells.
    Eur J Immunol. 1996 May;26(5):989-94 PMID: 8647190
  23. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
    Science. 1996 Jul 5;273(5271):109-12 PMID: 8658177
  24. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice.
    J Exp Med. 1996 Jun 1;183(6):2645-56 PMID: 8676085
  25. Myocyte remodeling during the progression to failure in rats with hypertension.
    Hypertension. 1996 Oct;28(4):609-14 PMID: 8843886
  26. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape.
    Science. 1996 Nov 22;274(5291):1363-6 PMID: 8910274
  27. Mouse islet cell lysis mediated by interleukin-1-induced Fas.
    Diabetologia. 1996 Nov;39(11):1306-12 PMID: 8932996
  28. The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines.
    J Card Fail. 1996 Dec;2(4 Suppl):S165-72 PMID: 8951575
  29. Antitumor effect of locally produced CD95 ligand.
    Nat Med. 1997 Feb;3(2):165-70 PMID: 9018234
  30. Immune response and myoblasts that express Fas ligand.
    Science. 1997 Nov 14;278(5341):1322-4 PMID: 9411754
  31. Gene transfer of Fas ligand induces tumor regression in vivo.
    Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13862-7 PMID: 9391118
  32. Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1213-7 PMID: 9448311
  33. Fas ligand gene transfer to renal allografts in rats: effects on allograft survival.
    Transplantation. 1998 Jan 27;65(2):155-60 PMID: 9458007
  34. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation.
    Nat Med. 1998 Apr;4(4):415-20 PMID: 9546786
  35. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.
    Circulation. 1998 Apr 14;97(14):1375-81 PMID: 9577949
  36. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats.
    Circulation. 1998 Apr 14;97(14):1382-91 PMID: 9577950
  37. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    J Immunol. 1998 Jun 1;160(11):5669-75 PMID: 9605174
  38. Chemotactic activity of soluble Fas ligand against phagocytes.
    J Immunol. 1998 Nov 1;161(9):4484-8 PMID: 9794371
  39. Regulation of the proinflammatory effects of Fas ligand (CD95L).
    Science. 1998 Nov 27;282(5394):1714-7 PMID: 9831564
  40. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid.
    Transplantation. 1998 Dec 15;66(11):1416-23 PMID: 9869081
  41. Accelerated rejection of Fas ligand-expressing heart grafts.
    J Immunol. 1999 Jan 1;162(1):518-22 PMID: 9886428
  42. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes.
    J Immunol. 1999 Mar 15;162(6):3601-6 PMID: 10092820
  43. Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes.
    Circulation. 1997 Mar 4;95(5):1247-52 PMID: 9054856
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2000-05-00
Pages
1199-208
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC378206
Subset
IM
Grants
NIAID NIH HHS · AI40394 · United States
NHLBI NIH HHS · HL41496 · United States
NHLBI NIH HHS · P50 HL052318 · United States
NHLBI NIH HHS · R01 HL056370 · United States
NHLBI NIH HHS · HL56370 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com